ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

PEEP Titration in ARDS Roundtable

PulmPEEPs

D. Furfaro, K. Montemayor, S. Sahetya, T. Rice, E. Baedorf-Kassis, R. Brower

HFpEF in Women

Scripps Health

B. Borlaug

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

SGLT2 Inhibition in 2024: Use in Heart Failure and Mechanism of Acti…

28th Annual Heart Failure 2024: An Update on Therapy

M. Packer

Hemodynamic vs. Hemo-Metabolic Shock: Redefining Shock Profiles

The Cardiogenic Shock Working Group

N. Kapur

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Contemporary Management of Cardiogenic Shock: Updates in 2022

Mount Sinai Advanced Innovations in Heart Failure

D. Baran

Cardiotoxicity: Anthracyclines

Scripps Health

M. Davis

High-Risk Cardiac Surgery and Pre-Op Optimization with Impella Base …

St. Louis Shock & Heart Failure Symposium 2022

J. Leidenfrost

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

The Valve Trials Are Done: Interventional HFpEF Is the Next Big Thing

Northwestern Medicine Bluhm Cardiovascular Institute

S. Shah

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin

Q&A: Organizing ECMO and ECLS for VF Cardiac Arrest

7th Annual Western New England Acute Cardiology Conference

D. Yannopoulos, A. Lotfi